Chairs: Prof. Dr Raquel Duarte (Porto, Portugal), Prof. Dr Christoph Lange (Borstel, Germany)
Speaker: Prof. Dr Michael Hoelscher (Munich, Germany)

Discussants: Dr Marion Holzapfel (Lyon, France), Dr Abdullah Alsultan (Riyadh, Saudi Arabia)

Fees: Free for ERS members and non-members
Find out more about becoming a member

Overview

Tuberculosis (TB) continues to be a significant global health threat. The use of antibiotics in the treatment of millions of TB patients per year will inevitably lead to the development of resistant strains, presenting a considerable challenge to treatment success. Resistance development can be minimised by optimising regimens (e.g combination of drugs, the right doses, etc.) improving patient adherence, etc.

However, there is a need to constantly develop novel anti-tuberculosis drugs and integrate them into novel regimens. This process is very complex, expensive and time consuming and requires the interplay between many partners. Several new compounds are presently in the clinical pipeline, promising shorter, safer, and more effective treatment regimens. However, their integration into standard clinical practice necessitates a comprehensive understanding of their mechanisms of action, efficacy, safety profiles, and potential interactions. This webinar will offer an update on the latest advancements in TB drug development.

Topics:

• Overview of current TB treatment challenges and drug resistance
• New and emerging TB drugs in the pipeline
• Clinical trial updates
• Considerations for integrating new drugs into treatment regimens
• Future directions and research gaps

Format

One-hour webinar format: 45 minutes for presentation, followed by a 15-minute Q&A session.

Learning outcomes

Following this webinar, participants will be able to:

• Identify the key new drugs in development for TB treatment
• Evaluate the clinical trial evidence supporting their efficacy and safety
• Understand potential challenges in implementing new regimens
• Discuss how these drugs can fit into current TB treatment guidelines
• Apply new knowledge to improve patient outcomes and TB control strategies

CME credit

An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.

What is a webinar?

A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Login guidelines

More information will be communicated in due course.

• Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
• Check Central European Time.
• To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
• Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

About UNITE4TB

UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: www.unite4TB.org

 

Funding

 

The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu

 

Disclaimer

 

This communication reflects the author's view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.